{"id":39671,"date":"2025-08-19T17:38:36","date_gmt":"2025-08-19T09:38:36","guid":{"rendered":"https:\/\/flcube.com\/?p=39671"},"modified":"2025-08-19T17:39:27","modified_gmt":"2025-08-19T09:39:27","slug":"kangtai-biological-gains-nmpa-approval-for-trivalent-influenza-vaccine-clinical-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39671","title":{"rendered":"Kangtai Biological Gains NMPA Approval for Trivalent Influenza Vaccine Clinical Trial"},"content":{"rendered":"\n

Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601<\/a>) announced that it has received approval from China’s National Medical Products Administration (NMPA) to conduct a clinical study for its trivalent influenza virus split vaccine (MDCK cells). This approval marks a significant step forward in the development of this innovative vaccine.<\/p>\n\n\n\n

Vaccine Profile<\/strong>
The trivalent influenza virus split vaccine (MDCK cells) is designed for individuals aged 3 years and above. It stimulates the body to produce immunity against influenza viruses, helping to prevent influenza caused by vaccine-related strains. This vaccine leverages MDCK cells, which are known for their easy cultivation, rapid proliferation, and susceptibility to influenza viruses.<\/p>\n\n\n\n

Production Advantages<\/strong>
By cultivating influenza viruses on a large scale in MDCK cells, the vaccine achieves higher production yields, more stable product quality, and lower production costs. Currently, no trivalent influenza virus split vaccine (MDCK cells) has been approved for marketing in China.<\/p>\n\n\n\n

Global Context<\/strong>
Overseas manufacturers such as Seqirus have already gained approval for MDCK cell-based influenza vaccines. Kangtai Biological’s entry into this field represents a new milestone in China’s vaccine industry.-Fineline Info & Tech<\/a><\/p>\n\n\n\n